Does lithium attenuate the liver damage due to oxidative stress and liver glycogen depletion in experimental common bile duct obstruction?
Copyright © 2023 Elsevier Inc. All rights reserved..
In extrahepatic cholestasis, the molecular mechanisms of liver damage due to bile acid accumulation remain elusive. In this study, the activation of glutamatergic receptors was hypothesized to be responsible for bile acid-induced oxidative stress and liver damage. Recent evidence showed that lithium, as an N-methyl-d-aspartate receptor (NMDAR) GluN2B subunit inhibitor, may act on the glutamate/NMDAR signaling axis. Guinea pigs were assigned to four groups, as sham laparotomy (SL), bile duct ligated (BDL), lithium-treated SL (SL + Li) and lithium-treated BDL (BDL + Li) groups. Cholestasis-induced liver injury was evaluated by aspartate aminotransferase (AST), alanine transaminase (ALT), interleukin-6 (IL-6), tissue malondialdehyde (MDA), copper‑zinc superoxide dismutase and reduced glutathione levels. The liability of glutamate/NMDAR signaling axis was clarified by glutamate levels in both plasma and liver samples, with the production of nitric oxide (NO), as well as with the serum calcium concentrations. Blood glucose, glucagon, insulin levels and glucose consumption rates, in addition to tissue glycogen were measured to evaluate the liver glucose-glycogen metabolism. A high liver damage index (AST/ALT) was calculated in BDL animals in comparison to SL group. In the BDL animals, lithium reduced plasma NO and glutamate in addition to tissue glutamate concentrations, while serum calcium increased. The antioxidant capacities and liver glycogen contents significantly increased, whereas blood glucose levels unchanged and tissue MDA levels decreased 3-fold in lithium-treated cholestatic animals. It was concluded that lithium largely protects the cholestatic hepatocyte from bile acid-mediated damage by blocking the NMDAR-GluN2B subunit.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:466 |
|---|---|
| Enthalten in: |
Toxicology and applied pharmacology - 466(2023) vom: 01. Mai, Seite 116489 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Engin, Ayse Basak [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.09.2023 Date Revised 07.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.taap.2023.116489 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354686518 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354686518 | ||
| 003 | DE-627 | ||
| 005 | 20231226062742.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.taap.2023.116489 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1182.xml |
| 035 | |a (DE-627)NLM354686518 | ||
| 035 | |a (NLM)36963521 | ||
| 035 | |a (PII)S0041-008X(23)00127-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Engin, Ayse Basak |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Does lithium attenuate the liver damage due to oxidative stress and liver glycogen depletion in experimental common bile duct obstruction? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.09.2023 | ||
| 500 | |a Date Revised 07.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a In extrahepatic cholestasis, the molecular mechanisms of liver damage due to bile acid accumulation remain elusive. In this study, the activation of glutamatergic receptors was hypothesized to be responsible for bile acid-induced oxidative stress and liver damage. Recent evidence showed that lithium, as an N-methyl-d-aspartate receptor (NMDAR) GluN2B subunit inhibitor, may act on the glutamate/NMDAR signaling axis. Guinea pigs were assigned to four groups, as sham laparotomy (SL), bile duct ligated (BDL), lithium-treated SL (SL + Li) and lithium-treated BDL (BDL + Li) groups. Cholestasis-induced liver injury was evaluated by aspartate aminotransferase (AST), alanine transaminase (ALT), interleukin-6 (IL-6), tissue malondialdehyde (MDA), copper‑zinc superoxide dismutase and reduced glutathione levels. The liability of glutamate/NMDAR signaling axis was clarified by glutamate levels in both plasma and liver samples, with the production of nitric oxide (NO), as well as with the serum calcium concentrations. Blood glucose, glucagon, insulin levels and glucose consumption rates, in addition to tissue glycogen were measured to evaluate the liver glucose-glycogen metabolism. A high liver damage index (AST/ALT) was calculated in BDL animals in comparison to SL group. In the BDL animals, lithium reduced plasma NO and glutamate in addition to tissue glutamate concentrations, while serum calcium increased. The antioxidant capacities and liver glycogen contents significantly increased, whereas blood glucose levels unchanged and tissue MDA levels decreased 3-fold in lithium-treated cholestatic animals. It was concluded that lithium largely protects the cholestatic hepatocyte from bile acid-mediated damage by blocking the NMDAR-GluN2B subunit | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Extrahepatic cholestasis | |
| 650 | 4 | |a Glutamate | |
| 650 | 4 | |a Hydrophobic bile acids | |
| 650 | 4 | |a Lithium | |
| 650 | 4 | |a Liver glycogen | |
| 650 | 4 | |a N-methyl-d-aspartate receptor | |
| 650 | 7 | |a Bile Acids and Salts |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Calcium |2 NLM | |
| 650 | 7 | |a SY7Q814VUP |2 NLM | |
| 650 | 7 | |a Glutamates |2 NLM | |
| 650 | 7 | |a Lithium |2 NLM | |
| 650 | 7 | |a 9FN79X2M3F |2 NLM | |
| 650 | 7 | |a Lithium Compounds |2 NLM | |
| 650 | 7 | |a Liver Glycogen |2 NLM | |
| 700 | 1 | |a Engin, Atilla |e verfasserin |4 aut | |
| 700 | 1 | |a Engin, Evren Doruk |e verfasserin |4 aut | |
| 700 | 1 | |a Memis, Leyla |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Toxicology and applied pharmacology |d 1959 |g 466(2023) vom: 01. Mai, Seite 116489 |w (DE-627)NLM000010979 |x 1096-0333 |7 nnns |
| 773 | 1 | 8 | |g volume:466 |g year:2023 |g day:01 |g month:05 |g pages:116489 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.taap.2023.116489 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 466 |j 2023 |b 01 |c 05 |h 116489 | ||